Form 4: Procept BioRobotics Director Antal Rohit Desai Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director Antal Rohit Desai of Procept BioRobotics Corp. executed multiple sales of common stock between September 3rd and September 5th, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Antal Rohit Desai, a director of Procept BioRobotics Corp, sold shares of common stock between September 3rd and September 5th, 2024.
- The sales were executed under a Rule 10b5-1 trading plan adopted on May 30, 2024.
- On September 3rd, Desai sold 10,766 shares at an average price of $75.1713, 19,725 shares at an average price of $76.3178, 3,629 shares at an average price of $77.2273, 1,000 shares at an average price of $77.999, and 100 shares at $78.91.
- On September 4th, Desai sold 6,222 shares at an average price of $74.9083, 10,998 shares at an average price of $75.697, 200 shares at an average price of $76.405, and 12,648 shares at an average price of $74.8991.
- Additionally, shares held indirectly by The 2:22 DNA Trust were sold on September 4th, including 23,164 shares at an average price of $75.6886 and 400 shares at an average price of $76.3675.
- On September 5th, shares held by The 2:22 DNA Trust were sold, including 12,405 shares at an average price of $76.3259 and 900 shares at an average price of $76.9578.
- Following these transactions, Desai directly owns 6,543 shares and indirectly owns 317,518 shares through The 2:22 DNA Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock sales by a company director under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider trading activity. It is common for corporate insiders to set up 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.
Stakeholder Impact
- The share sales could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2024-05-30 | Date the reporting person adopted a Rule 10b5-1 Trading Plan |
| 2024-09-03 | Date of earliest transaction reported |
| 2024-09-05 | Date of last transaction reported |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.